View Document Preview and Link Document Date: 2012-09-04 15:12:58 Open Document File Size: 461,33 KB Share Result on Facebook
Company Agency for Healthcare Research / / Facility University of Alberta Evidence-based Practice Center / Baylor College of Medicine / AHRQ Pub / / MedicalCondition Tourette’s syndrome / Pediatric Use FGAs Generic Name Approved Age Group Approved Age Group Schizophrenia / attention deficit hyperactivity disorder / psychiatric disorders / schizophrenia / anorexia nervosa / particular disorder / disruptive behavior disorders / pediatric psychiatric disorders / obsessive-compulsive / autism / dyslipidemia / mania / adolescent psychiatric disorders / ADHD/disruptive behavior disorders / bipolar disorder / obsessive-compulsive disorder / post-traumatic stress disorder / pervasive developmental disorders / / Organization Baylor College of Medicine / Houston / University of Alberta / Alberta Evidence-based Practice Center / U.S. Food and Drug Administration / John M. Eisenberg Center for Clinical Decisions and Communications Science / Agency for Healthcare Research and Quality / / / Product olanzapine / clozapine / risperidone / Prochlorperazine / Perphenazine / haloperidol / Loxapine / Thiothixene / / URL www.effectivehealthcare.ahrq / www.effectivehealthcare.ahrq.gov/pedantipsych.cfm / / SocialTag 
Clinician Research Summary Mental Health Atypical Antipsychotics First- and Second-Generation Antipsychotics for Children: